Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4508 in Advanced Solid Tumors
NCT06598735Phase 1Recruiting
- Sponsor
- Hengrui
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-4508 in solid tumor, sponsored by Hengrui. Primary endpoints: Number of subjects with adverse events and the severity of adverse events at 5 months, Dose-limiting toxicity at 3 weeks and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
HRS-4508
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06598735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598735.